Compare · CLPT vs SYK
CLPT vs SYK
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 382.5x CLPT ($294.1M).
- SYK has been more active in the news (8 items in the past 4 weeks vs 3 for CLPT).
- SYK has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- ClearPoint Neuro Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $294.1M
- $112.48B
- 1M return
- -
- +5.16%
- 1Y return
- -
- -21.34%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 8
- Recent ratings
- 5
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest CLPT
- ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026
- Director Richards Timothy T. was granted 319 shares, increasing direct ownership by 0.36% to 87,863 units (SEC Form 4)
- Director Fletcher R John was granted 993 shares, increasing direct ownership by 0.76% to 132,004 units (SEC Form 4)
- CEO and President Burnett Joseph exercised 12,517 shares at a strike of $3.47, increasing direct ownership by 11% to 130,720 units (SEC Form 4)
- SEC Form 10-Q filed by ClearPoint Neuro Inc.
- ClearPoint Neuro Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ClearPoint Neuro Reports Second Quarter 2026 Results
- ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
- ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
- Director Richards Timothy T. was granted 222 shares, increasing direct ownership by 0.25% to 87,544 units (SEC Form 4)
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)